Core Viewpoint - Dongyangguang Pharmaceutical (06887.HK) has entered into a strategic cooperation agreement with Shenzhen Jingtai Technology Co., Ltd. to establish a joint venture focused on AI-driven drug research and development [1][2] Group 1: Joint Laboratory and Drug Development - The agreement includes the establishment of a joint laboratory aimed at developing innovative drug pipelines, focusing on autoimmune diseases through an AI-driven automated research process [1] - The collaboration will leverage Shenzhen Jingtai's automated experimental platform technology to create a closed-loop R&D process encompassing design, construction, testing, and learning [1] Group 2: AI Model Development and Promotion - The partnership aims to develop and promote a PB-PK predictive model that aligns with industry-leading commercial software, utilizing high-quality non-clinical data from the company and AI algorithms from Shenzhen Jingtai [1] - A comprehensive AI drug development engine covering the entire drug development lifecycle will be co-created, incorporating the company's proprietary models such as HEC-SynAI and HEC-PharmAI [1] Group 3: Business Model Creation - The companies plan to establish a "Model as a Service" (MaaS) business model, which will involve building an AI supercomputing platform that supports collaboration with academia and industry [2] - The strategic cooperation is expected to create mutual benefits and synergies by leveraging each party's resources and expertise, aligning with the overall interests of the company and its shareholders [2]